Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

NCT00076440 is registered in ClinicalTrials.gov with Voyager Pharmaceutical Corporation as lead sponsor.

NCT NCT00076440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00076440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
Lead sponsor
Voyager Pharmaceutical Corporation
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
March 31, 2007
Enrollment
90
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease